Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Adagio Therapeutics, Inc. Market Cap
From what 0 stock analysts predict, the share price for Adagio Therapeutics, Inc. (ADGI) might decrease by 100% in the next year. This is based on a 12-month average estimation for ADGI. Price targets go from $ to $. The majority of stock analysts believe ADGI is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
Adagio Therapeutics, Inc. has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Adagio Therapeutics, Inc. will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of ADGI.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Morgan Stanley | Underweight | Maintains | Sep 16, 2022 | |
Morgan Stanley | Underweight | Initiates | Sep 14, 2022 | |
| Matthew Harrison Morgan Stanley | Underweight | $3 | Maintains | May 17, 2022 |
| Matthew Harrison Morgan Stanley | Underweight | $6 | Downgrade | Jan 6, 2022 |
Jefferies | Hold | $10 | Downgrade | Dec 22, 2021 |
| Stephen Willey Stifel | Hold | $9 | Downgrade | Dec 15, 2021 |
Guggenheim | Neutral | Downgrade | Dec 15, 2021 | |
| Matthew Harrison Morgan Stanley | Equal-Weight | $11 | Downgrade | Dec 15, 2021 |
Morgan Stanley | Overweight | Upgrade | Nov 29, 2021 | |
Guggenheim | Buy | Initiates | Aug 31, 2021 | |
Stifel | Buy | Initiates | Aug 31, 2021 | |
Jefferies | Buy | Initiates | Aug 31, 2021 | |
Morgan Stanley | Equal-Weight | Initiates | Aug 31, 2021 |
When did it IPO
2021
Staff Count
0
Country
United States
Sector/Industry
/
CEO
Market Cap
$38.5M
In 2023, ADGI generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ADGI's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 16 Mar 2023
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Investors in Invivyd, Inc. (NASDAQ: IVVD) who purchased shares between Nov 29 and Dec 14, 2021, have until April 3, 2023, to file for potential compensation at no upfront cost.
Why It Matters - The deadline for lead plaintiff claims may impact Invivyd's stock price and investor sentiment, indicating potential legal risks and financial liabilities for the company.
Wed, 08 Mar 2023
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Invivyd, Inc. shareholders who bought securities between Nov 29 and Dec 14, 2021, are reminded of the April 3, 2023, lead plaintiff deadline for potential compensation claims.
Why It Matters - The news signals potential legal claims for Invivyd investors, indicating possible compensation opportunities, which could affect stock sentiment and future trading activity.
Thu, 02 Mar 2023
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Rosen Law Firm reminds Invivyd, Inc. (NASDAQ: IVVD) investors of an April 3, 2023 lead plaintiff deadline for potential compensation related to securities purchased between Nov 29 and Dec 14, 2021.
Why It Matters - The announcement of a lead plaintiff deadline signals potential legal actions that could impact Invivyd's stock price, affecting shareholder value and investment decisions.
Wed, 22 Feb 2023
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Investors in Invivyd, Inc. (NASDAQ: IVVD) from Nov 29 to Dec 14, 2021, should note the April 3, 2023, deadline to file a lead plaintiff claim for potential compensation. No upfront fees required.
Why It Matters - The announcement highlights a potential legal action for investors in Invivyd, indicating possible financial compensation, which could impact stock value and investor sentiment.
Thu, 16 Feb 2023
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Investors in Invivyd, Inc. (NASDAQ: IVVD) from Nov 29 to Dec 14, 2021, are reminded of the April 3, 2023, lead plaintiff deadline for potential compensation without out-of-pocket costs.
Why It Matters - The announcement highlights a lead plaintiff deadline for a class action lawsuit against Invivyd, which could impact stock valuation and investor sentiment.
Mon, 13 Feb 2023
Sentiment - NEUTRAL
Source - Newsfile Corp
Summary - Rosen Law Firm alerts investors in Invivyd, Inc. (NASDAQ: IVVD) from Nov 29 to Dec 14, 2021, of the April 3, 2023 lead plaintiff deadline for a securities class action.
Why It Matters - The reminder about the lead plaintiff deadline signals potential legal actions, which could impact Invivyd's stock price and investor sentiment. Legal risks can influence investment decisions.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
